Private hospital shares declined following Supreme Court concerns over high mark-ups on medicines. Investors are now assessing the risk of tighter regulatory caps on pharmacy margins and operational restrictions ahead of the next court hearing.
The Indian healthcare sector experienced a market correction in late September following strong observations from the Supreme Court regarding pricing practices at private hospitals. The judicial body expressed significant concern over the high mark-ups on medical consumables and medicines, specifically citing a case where a cancer drug was reportedly procured for roughly Rs 2,700 but sold to patients for Rs 27,000.
This criticism rattled market sentiment, leading to a decline in hospital stocks on September 30. The BSE Healthcare Hospitals Index fell by approximately 5% that day. Among the major players, Apollo Hospitals recorded a decline of 5.7%, while Fortis Healthcare and Max Healthcare saw their shares drop by 6.3% and 5.3%, respectively.
Investors are reacting to the possibility that this judicial attention could translate into stricter government intervention. The central concerns include the potential for official caps on pharmacy margins—possibly at a 16% limit similar to other regulated segments—and restrictions on the practice of mandating that patients purchase medicines from in-house hospital pharmacies. These business models have historically been a significant revenue and profit contributor for many private healthcare chains.
From a financial perspective, the sector has been trading at high valuation multiples, with EV/EBITDA ratios in the mid-to-high 20s. This elevated valuation has made the industry sensitive to regulatory news, as any compression in profit margins could impact the growth expectations priced into these stocks. Beyond regulatory risks, hospitals are already managing internal cost pressures, including rising expenses for doctor compensation and the need for significant capital spending to expand capacity. If hospitals are forced to adjust their pricing models or revenue streams from pharmacies, it may place additional pressure on their overall operating margins.
As of early October 2026, the situation remains fluid, as no final regulatory cap has been ordered by the court. The current market reaction is largely driven by risk assessment rather than an immediate change in business operations. The matter is listed for a further hearing on October 12, 2026. Investors will be closely watching for government filings or any concrete policy directions emerging from that session to understand the long-term impact on hospital profitability.